Neurocrine Biosciences (NBIX) Tops Q4 EPS by 30c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.64 -1.71%
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.05, $0.30 better than the analyst estimate of $0.75. Revenue for the quarter came in at $244.1 million versus the consensus estimate of $230.94 million.
Full-Year 2020 Financial Guidance | |||||||||||||||
Range | |||||||||||||||
(in millions) | Low | High | |||||||||||||
Combined GAAP R&D and SG&A expenses | $ | 740 | $ | 770 | |||||||||||
Combined Non-GAAP R&D and SG&A expenses | $ | 620 | $ | 650 | |||||||||||
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
